The Parkinson's disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway

Nature Communications

Volumn 7, Issue , 2016, Pages

  Bento, Carla F ^a   Ashkenazi, Avraham ^a   Jimenez Sanchez, Maria ^a   Rubinsztein, David C ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATASE 13A2; ALPHA SYNUCLEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; SYNAPTOTAGMIN; SYNAPTOTAGMIN 11; TUBERIN; UNCLASSIFIED DRUG; ATP13A2 PROTEIN, HUMAN; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; MESSENGER RNA; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; SYT11 PROTEIN, HUMAN; TFEB PROTEIN, HUMAN;

BIODEGRADATION; DISEASE INCIDENCE; GENE EXPRESSION; MUTATION; NERVOUS SYSTEM; PROTEIN;

ANIMAL CELL; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; CONFOCAL MICROSCOPY; CONSENSUS SEQUENCE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; ENZYME ACTIVITY; FEMALE; FLUORESCENCE MICROSCOPY; GENE CONTROL; GENE EXPRESSION; GENETIC ASSOCIATION; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; LYSOSOME; MOUSE; NERVE CELL CULTURE; NEUROBLASTOMA CELL; NONHUMAN; PARKINSON DISEASE; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIMARY CELL CULTURE; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN STABILITY; REAL TIME POLYMERASE CHAIN REACTION; REPRESSOR GENE; TANDEM MASS SPECTROMETRY; TRANSCRIPTION INITIATION; TRANSCRIPTION INITIATION SITE; UBIQUITINATION; GENETICS; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

AUTOPHAGY; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; HELA CELLS; HUMANS; LYSOSOMES; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; PARKINSON DISEASE; PROTON-TRANSLOCATING ATPASES; RNA, MESSENGER; SIGNAL TRANSDUCTION; SYNAPTOTAGMINS; UBIQUITINATION;

EID: 84973596577     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11803     Document Type: Article

References (60)

1. Frake, R. A., Ricketts, T., Menzies, F. M. & Rubinsztein, D. C. Autophagy and neurodegeneration. J. Clin. Invest. 125, 65-74 (2015).
2. Schultz, M. L., Tecedor, L., Chang, M. & Davidson, B. L. Clarifying lysosomal storage diseases. Trends Neurosci. 34, 401-410 (2011).
3. Decressac, M. et al. TFEB-mediated autophagy rescues midbrain dopamine neurons from alpha-synuclein toxicity. Proc. Natl Acad. Sci. USA 110, E1817-E1826 (2013).
4. Dehay, B. et al. Pathogenic lysosomal depletion in Parkinson's disease. J. Neurosci. 30, 12535-12544 (2010).
5. Dehay, B. et al. Loss of P-type ATPase ATP13A2/PARK9 function induces general lysosomal deficiency and leads to Parkinson disease neurodegeneration. Proc. Natl Acad. Sci. USA 109, 9611-9616 (2012).
6. Park, J. S. et al. Pathogenic effects of novel mutations in the P-type ATPase ATP13A2 (PARK9) causing Kufor-Rakeb syndrome, a form of early-onset parkinsonism. Hum. Mutat. 32, 956-964 (2011).
7. Ramirez, A. et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet. 38, 1184-1191 (2006).
8. Usenovic, M., Tresse, E., Mazzulli, J. R., Taylor, J. P. & Krainc, D. Deficiency of ATP13A2 leads to lysosomal dysfunction, alpha-synuclein accumulation, and neurotoxicity. J. Neurosci. 32, 4240-4246 (2012).
9. Gitler, A. D. et al. Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat. Genet. 41, 308-315 (2009).
10. Lill, C. M. et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet. 8, e1002548 (2012).
11. Nalls, M. A. et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 377, 641-649 (2011).
12. Sharma, M. et al. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology 79, 659-667 (2012).
13. Nalls, M. A. et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46, 989-993 (2014).
14. Inoue, S. et al. Synaptotagmin XI as a candidate gene for susceptibility to schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 332-340 (2007).
15. Usenovic, M. et al. Identification of novel ATP13A2 interactors and their role in alpha-synuclein misfolding and toxicity. Hum. Mol. Genet. 21, 3785-3794 (2012).
16. Sudhof, T. C. Calcium control of neurotransmitter release. Cold Spring Harb. Perspect. Biol. 4, a011353 (2012).
17. Arango Duque, G., Fukuda, M. & Descoteaux, A. Synaptotagmin XI regulates phagocytosis and cytokine secretion in macrophages. J. Immunol. 190, 1737-1745 (2013).
18. Sardiello, M. et al. A gene network regulating lysosomal biogenesis and function. Science 325, 473-477 (2009).
19. Palmieri, M. et al. Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways. Hum. Mol. Genet. 20, 3852-3866 (2011).
20. Settembre, C. et al. A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB. EMBO J. 31, 1095-1108 (2012).
21. Martina, J. A. & Puertollano, R. Rag GTPases mediate amino acid-dependent recruitment of TFEB and MITF to lysosomes. J. Cell. Biol. 200, 475-491 (2013).
22. Thoreen, C. C. et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 284, 8023-8032 (2009).
23. Sancak, Y. et al. Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. Cell 141, 290-303 (2010).
24. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 8, 445-544 (2012).
25. Han, S. et al. Pam (protein associated with Myc) functions as an E3 ubiquitin ligase and regulates TSC/mTOR signaling. Cell Signal. 20, 1084-1091 (2008).
26. Inoki, K., Li, Y., Zhu, T., Wu, J. & Guan, K. L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648-657 (2002).
27. Kabeya, Y. et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J. 19, 5720-5728 (2000).
28. Kimura, S., Noda, T. & Yoshimori, T. Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. Autophagy 3, 452-460 (2007).
29. Ishidoh, K. & Kominami, E. Processing and activation of lysosomal proteinases. Biol. Chem. 383, 1827-1831 (2002).
30. Turk, V., Turk, B. & Turk, D. Lysosomal cysteine proteases: facts and opportunities. EMBO J. 20, 4629-4633 (2001).
31. Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N. & Rubinsztein, D. C. Alpha-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009-25013 (2003).
32. Settembre, C. et al. TFEB links autophagy to lysosomal biogenesis. Science 332, 1429-1433 (2011).
33. Park, J. S., Koentjoro, B., Veivers, D., Mackay-Sim, A. & Sue, C. M. Parkinson's disease-associated human ATP13A2 (PARK9) deficiency causes zinc dyshomeostasis and mitochondrial dysfunction. Hum. Mol. Genet. 23, 2802-2815 (2014).
34. Tsunemi, T. & Krainc, D. Zn(2)(+) dyshomeostasis caused by loss of ATP13A2/PARK9 leads to lysosomal dysfunction and alpha-synuclein accumulation. Hum. Mol. Genet. 23, 2791-2801 (2014).
35. Huynh, D. P., Scoles, D. R., Nguyen, D. & Pulst, S. M. The autosomal recessive juvenile Parkinson disease gene product, parkin, interacts with and ubiquitinates synaptotagmin XI. Hum. Mol. Genet. 12, 2587-2597 (2003).
36. Pawlyk, A. C. et al. Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J. Biol. Chem. 278, 48120-48128 (2003).
37. Grenier, K., McLelland, G. L. & Fon, E. A. Parkin- and PINK1-dependent mitophagy in neurons: will the real pathway please stand up? Front. Neurol. 4, 100 (2013).
38. Gusdon, A. M., Zhu, J., Van Houten, B. & Chu, C. T. ATP13A2 regulates mitochondrial bioenergetics through macroautophagy. Neurobiol. Dis. 45, 962-972 (2012).
39. Pastore, N. et al. Gene transfer of master autophagy regulator TFEB results in clearance of toxic protein and correction of hepatic disease in alpha-1-antitrypsin deficiency. EMBO Mol. Med. 5, 397-412 (2013).
40. Spampanato, C. et al. Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO Mol. Med. 5, 691-706 (2013).
41. Duvel, K. et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol. Cell 39, 171-183 (2010).
42. Hu, G. et al. A conserved mechanism of TOR-dependent RCK-mediated mRNA degradation regulates autophagy. Nat. Cell Biol. 17, 930-942 (2015).
43. Klionsky, D. J., Elazar, Z., Seglen, P. O. & Rubinsztein, D. C. Does bafilomycin A1 block the fusion of autophagosomes with lysosomes? Autophagy 4, 849-850 (2008).
44. Bar-Peled, L. & Sabatini, D. M. Regulation of mTORC1 by amino acids. Trends Cell Biol. 24, 400-406 (2014).
45. Hu, Y. et al. Lysosomal pH plays a key role in regulation of mTOR activity in osteoclasts. J. Cell Biochem. 117, 413-425 (2016).
46. Newton, P. T., Vuppalapati, K. K., Bouderlique, T. & Chagin, A. S. Pharmacological inhibition of lysosomes activates the MTORC1 signaling pathway in chondrocytes in an autophagy-independent manner. Autophagy 11, 1594-1607 (2015).
47. Zoncu, R. et al. mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H(+)-ATPase. Science 334, 678-683 (2011).
48. Sudhof, T. C. Synaptotagmins: why so many? J. Biol. Chem. 277, 7629-7632 (2002).
49. von Poser, C., Ichtchenko, K., Shao, X., Rizo, J. & Sudhof, T. C. The evolutionary pressure to inactivate. A subclass of synaptotagmins with an amino acid substitution that abolishes Ca2+ binding. J. Biol. Chem. 272, 14314-14319 (1997).
50. Dai, H. et al. Structural basis for the evolutionary inactivation of Ca2+ binding to synaptotagmin 4. Nat. Struct. Mol. Biol. 11, 844-849 (2004).
51. Wang, C. et al. Synaptotagmin-11 inhibits clathrin-mediated and bulk endocytosis. EMBO Rep. 17, 47-63 (2016).
52. Matheoud, D. et al. Leishmania evades host immunity by inhibiting antigen cross-presentation through direct cleavage of the SNARE VAMP8. Cell Host Microbe 14, 15-25 (2013).
53. Vinet, A. F., Fukuda, M., Turco, S. J. & Descoteaux, A. The Leishmania donovani lipophosphoglycan excludes the vesicular proton-ATPase from phagosomes by impairing the recruitment of synaptotagmin V. PLoS Pathog. 5, e1000628 (2009).
54. Larsen, K. B. et al. A reporter cell system to monitor autophagy based on p62/ SQSTM1. Autophagy 6, 784-793 (2010).
55. Manning, B. D., Tee, A. R., Logsdon, M. N., Blenis, J. & Cantley, L. C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10, 151-162 (2002).
56. Jimenez-Sanchez, M. et al. siRNA screen identifies QPCT as a druggable target for Huntington's disease. Nat. Chem. Biol. 11, 347-354 (2015).
57. Ran, F. A. et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380-1389 (2013).
58. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).
59. Cost, G. J. & Cozzarelli, N. R. Directed assembly of DNA molecules via simultaneous ligation and digestion. BioTechniques 42(84): 86-89 (2007).
60. Renna, M. et al. Autophagic substrate clearance requires activity of the syntaxin-5 SNARE complex. J. Cell. Sci. 124, 469-482 (2011).